Putative neuroprotective agents in neuropsychiatric disorders
Putative neuroprotective agents in neuropsychiatric disorders
复制标题
DOI：
10.1016/j.pnpbp.2012.11.007
复制
发表时间：
2013-04-05
影响因子：
5.6
通讯作者：
Berk, Michael
中科院分区：
文献类型：
--
作者：
Dodd, Seetal;Maes, Michael;Berk, Michael
在许多患有主要神经精神障碍（包括抑郁症、双相情感障碍和精神分裂症）的个体中，其疾病特征与神经进展性疾病一致。这包括进行性脑结构变化、认知和功能下降、治疗反应较差以及慢性复发的脆弱性增加。神经进展的潜在分子机制被认为包括神经营养因子和神经发生和细胞凋亡的调节、神经递质、炎症、氧化和亚硝化应激、线粒体功能障碍、皮质醇和下丘脑-垂体-肾上腺轴以及表观遗传影响。对这些通路中的每一个的参与的了解意味着作用于这些通路中的一些或多个的特定药剂可能因此阻断该级联并具有神经保护性质。本文综述了这些药物中最有前途的药物的潜力，包括锂和其他已知的精神药物，阿司匹林，米诺环素，他汀类药物，N-乙酰半胱氨酸，瘦素和褪黑激素。这些药物是精神分裂症和情绪障碍的假定神经保护剂。(C)2012 Elsevier Inc. All rights reserved.
In many individuals with major neuropsychiatric disorders including depression, bipolar disorder and schizophrenia, their disease characteristics are consistent with a neuroprogressive illness. This includes progressive structural brain changes, cognitive and functional decline, poorer treatment response and an increasing vulnerability to relapse with chronicity. The underlying molecular mechanisms of neuroprogression are thought to include neurotrophins and regulation of neurogenesis and apoptosis, neurotransmitters, inflammatory, oxidative and nitrosative stress, mitochondrial dysfunction, cortisol and the hypothalamic-pituitary-adrenal axis, and epigenetic influences. Knowledge of the involvement of each of these pathways implies that specific agents that act on some or multiple of these pathways may thus block this cascade and have neuroprotective properties. This paper reviews the potential of the most promising of these agents, including lithium and other known psychotropics, aspirin, minocydine, statins, N-acetylcysteine, leptin and melatonin. These agents are putative neuroprotective agents for schizophrenia and mood disorders. (C) 2012 Elsevier Inc. All rights reserved.